Nonrelapse mortality and overall survival stratified by the biomarker panel. (A) The cumulative incidence of nonrelapse mortality (NRM) and overall survival (OS), determined by Kaplan-Meier curve, is plotted according to the predicted probability of acute GVHD: low (—, n = 193) and high (----, n = 89). P = .001 and P = .006 (adjusted for age, donor type, HLA match, and intensity of conditioning) for differences in NRM and OS, respectively. The NRM at 3.5 years is 15% (95% CI, 9%-21%) for the low-risk group and 36% (95% CI, 24%-48%) for the high-risk group. OS at 3.5 years is 53% (95% CI, 45%-63%) for the low-risk group and 33% (95% CI, 22%-48%) in the high-risk group. (B) The cumulative incidence of NRM and OS of the 2 groups is plotted for the validation set: low (—, n = 93) and high (----, n = 49). P values less than .001 and .02 (adjusted as before) for differences in NRM and OS, respectively. The NRM at 3.5 years is 11% (95% CI, 4%-19%) for the low-risk group and 38% (95% CI, 23%-53%) for the high-risk group. OS at 3.5 years is 59% (95% CI, 49%-72%) for the low-risk group and 44% (95% CI, 31%-63%) for the high-risk group.